School of Chemistry and Chemical Engineering, Southwest University, Chongqing 400715, China.
Bioorg Med Chem. 2012 Mar 15;20(6):2119-30. doi: 10.1016/j.bmc.2012.01.028. Epub 2012 Feb 2.
We wish to report the further design and improved synthesis that resulted in two series of target molecules, TM-1 and TM-2, with remarkably simplified structures containing β-amino ketone of discrete nabumetone moiety. These were obtained via a 'one-pot, two-step, three-component' protocol of Mannich reaction with yield up to 97%. A total of 28 out of 31 new compounds were characterized using (1)H NMR, (13)C NMR, ESI MS and HRMS techniques. Studies on their antidiabetic activities, screened in vitro at 10 μg mL(-1) level, indicate that TM-2 possesses peroxisome proliferator-activated receptor activation and α-glucosidase inhibition activity significantly stronger than that of TM-1, and also that of the series B compounds that were previously synthesized by the group. Analysis of the structure-activity relationship points to the sulfanilamide unit as the most probable potent group of β-amino ketone and, on the basis of which, a tangible strategy is presented for the development of new antidiabetic drugs.
我们希望报告进一步的设计和改进合成,这导致了两个系列的靶分子,TM-1 和 TM-2,具有显著简化的结构,含有离散萘丁美酮部分的β-氨基酮。这些是通过曼尼希反应的“一锅两步三组分”方案获得的,产率高达 97%。总共 31 个新化合物中的 28 个使用 (1)H NMR、(13)C NMR、ESI MS 和 HRMS 技术进行了表征。在 10 μg mL(-1)水平的体外筛选中,对它们的抗糖尿病活性进行了研究,结果表明 TM-2 具有过氧化物酶体增殖物激活受体激活和α-葡萄糖苷酶抑制活性,明显强于 TM-1 以及之前由该小组合成的 B 系列化合物。构效关系分析表明磺胺基单位是β-氨基酮最可能的有效基团,在此基础上提出了开发新型抗糖尿病药物的切实可行策略。